Cantor says Arcturus’ detailed booster data validate STARR/LUNAR platforms

After Arcturus Therapeutics and partner Meiji Pharma released detailed data from their booster study for the next-generation mRNA vaccine ‘154 in a preprint on medRxiv, Cantor Fitzgerald noted that immune response four weeks after ARCT-154 booster dose were higher versus a Comirnaty booster, meeting noninferiority against the original SARS-CoV-2 virus, and that ‘154 showed superiority to Pfizer’s (PFE) Comirnaty against the Omicron BA.4/5 variant. The firm, which says the detailed data validate STARR/LUNAR platforms, has an Overweight rating and $54 price target on Arcturus shares.